Reply to: 'Rethinking "inactive chronic hepatitis B": should we treat patients with high HBsAg levels?'.
APA
Tseng TC, Yang HI, Kao JH (2026). Reply to: 'Rethinking "inactive chronic hepatitis B": should we treat patients with high HBsAg levels?'.. Gut, 75(4), 844-845. https://doi.org/10.1136/gutjnl-2025-336618
MLA
Tseng TC, et al.. "Reply to: 'Rethinking "inactive chronic hepatitis B": should we treat patients with high HBsAg levels?'.." Gut, vol. 75, no. 4, 2026, pp. 844-845.
PMID
41015493
같은 제1저자의 인용 많은 논문 (5)
- Molecular Milestones and Survival Outcomes of Ponatinib Treatment in Patients With Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: A Real-World Analysis.
- Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification.
- Reply: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in patients with chronic hepatitis B with immune-tolerant phase.
- Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients.
- Reply: Prevalence of serum HBsAg <100 IU/mL in inactive chronic hepatitis B.